Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
157.10
+0.44 (0.28%)
At close: Jun 13, 2025, 4:00 PM
157.14
+0.04 (0.03%)
After-hours: Jun 13, 2025, 7:55 PM EDT
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $21.89B in the quarter ending March 30, 2025, with 2.39% growth. This brings the company's revenue in the last twelve months to $89.33B, up 4.30% year-over-year. In the year 2024, Johnson & Johnson had annual revenue of $88.82B with 4.30% growth.
Revenue (ttm)
$89.33B
Revenue Growth
+4.30%
P/S Ratio
4.23
Revenue / Employee
$646,857
Employees
138,100
Market Cap
377.99B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
| Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
| Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
| Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
| Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
| Dec 29, 2019 | Pro | Pro | Pro |
| Dec 30, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Jan 1, 2017 | Pro | Pro | Pro |
| Jan 3, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
| Thermo Fisher Scientific | 42.90B |
JNJ News
- 12 hours ago - Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma - PRNewsWire
- 1 day ago - New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia - PRNewsWire
- 2 days ago - Johnson & Johnson (JNJ) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 2 days ago - New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis - PRNewsWire
- 3 days ago - Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors - Business Wire
- 7 days ago - Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector? - Market Watch
- 10 days ago - DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity - PRNewsWire
- 10 days ago - Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients - PRNewsWire